Symbol | Exchange | Currency |
|---|
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative diseases and psychiatric disorders. Its pipeline includes AL001, an ionic cocrystal technology delivering a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer’s and other neurodegenerative diseases, and psychiatric disorders; and AL002, a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient’s immunological system to combat Alzheimer’s. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Buy | Sell |
| Technical Indicators | Buy | Strong Buy | Strong Buy | Buy | Sell |
| Summary | Strong Buy | Strong Buy | Strong Buy | Buy | Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 419.41 | 420.78 | 406.74 | +19.76 | +4.94% | 682.06K | NASDAQ | |||
| 39.75 | 39.84 | 38.13 | +1.94 | +5.13% | 1.79M | NYSE | |||
| 135.21 | 148.37 | 131.53 | -6.81 | -4.80% | 4.23M | NYSE | |||
| 495.64 | 499.76 | 486.56 | -4.17 | -0.83% | 13.01M | NYSE | |||
| 509.09 | 511.80 | 501.45 | +12.51 | +2.52% | 2.11M | NASDAQ | |||
| 2.36 | 3.86 | 2.20 | -0.3700 | -13.55% | 65.17M | NASDAQ | |||
| 51.27 | 51.97 | 50.46 | +0.84 | +1.67% | 1.82M | NYSE | |||
| 2.06 | 2.14 | 2.047 | 0.000 | 0.00% | 262.57K | NASDAQ | |||
| 31.34 | 31.64 | 31.19 | +0.11 | +0.35% | 4.38M | NYSE | |||
| 13.47 | 13.94 | 12.44 | -0.03 | -0.22% | 4.19M | NASDAQ | |||
| 38.66 | 39.03 | 37.78 | +1.27 | +3.40% | 1.85M | NYSE | |||
| 0.51 | 0.55 | 0.49 | +0.02 | +4.07% | 39.48M | NASDAQ | |||
| 38.16 | 38.36 | 36.15 | +1.51 | +4.12% | 7.27M | NYSE | |||
| 249.29 | 249.36 | 237.78 | +9.73 | +4.06% | 936.68K | NYSE | |||
| 14.99 | 15.19 | 14.50 | +0.55 | +3.81% | 3.55M | NYSE |